Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Chimeric and humanised monoclonal antibodies against interleukin-13

A humanized antibody and humanized technology, applied in the field of immunoglobulin

Inactive Publication Date: 2007-09-19
GLAXO GROUP LTD
View PDF54 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, when comparing bleomycin-induced lung fibrosis in C57BL6 / J mice (overexpressing IL-4), IL-4 knockout and wild type, Izbicki et al. 2002 283(5): L1110-L1116) found no evidence to support the involvement of IL-4 in pulmonary fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Chimeric and humanised monoclonal antibodies against interleukin-13
  • Chimeric and humanised monoclonal antibodies against interleukin-13
  • Chimeric and humanised monoclonal antibodies against interleukin-13

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0339] 1. Preparation of monoclonal antibody and study of mouse monoclonal antibody 6A1

[0340] Monoclonal antibodies (mAbs) are generally prepared from hybridoma cells as taught by E Harlow and D Lane in Antibodies a Laboratory Manual, Cold Spring Harbor Laboratory, 1988 . As a result, the fusion of mouse myeloma cells and mouse B lymphocytes immunized with the target antigen was obtained. Hybridoma cells acquire the ability to proliferate indefinitely with the help of myeloma fusion partners, while the ability to produce antibodies is provided by B lymphocytes.

[0341] Five SJL mice were immunized by intraperitoneal injection of 2 μg each of E. coli-derived recombinant human IL-13 (Cambridge Bioscience, Cat. No. CH-013). The vaccination procedure used produced high titer anti-human IL-13 antibody immune responses in mice. After 5 inoculations within 64 days, mice were sacrificed and splenocytes were collected. Splenocytes from three mice were removed, and B lymphocytes ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention concerns immunoglobulins, particularly antibodies which specifically bind human Interleukin 13 (hIL-13). Antibodies of the invention may be used in the treatment of a variety of diseases or disorders responsive to modulation of the interaction between hIL-13 and the human IL-13 receptor. Such diseases include severe asthma, atopic dermatitis, COPD and various fibrotic diseases. Pharmaceutical compositions comprising said antibodies and methods of manufacture are also disclosed.

Description

technical field [0001] The present invention relates to immunoglobulins that specifically bind to interferon 13 (IL-13), especially human IL-13 (hIL-13). One embodiment of the invention relates to antibodies that specifically bind hIL-13. The present invention also relates to methods for treating diseases or disorders using the immunoglobulins, pharmaceutical compositions containing the immunoglobulins and methods for their preparation. Other aspects of the invention will be apparent from the following description. Background technique [0002] Interleukin-13 (IL-13) [0003] IL-13 is a 12 kDa secreted cytokine that was previously described as a T cell-derived cytokine capable of suppressing inflammatory cytokine production. Structural studies show that it has a four-helical bundle held together by two disulfide bonds. Although IL-13 has four potential glycosylation sites, analysis of native IL-13 in rat lungs revealed that it is produced as an unglycosylated molecule. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/24A61P37/02A61P37/08A61K39/00
CPCY02A50/30
Inventor 克莱尔·阿什曼马丁·J·卡西迪乔纳森·H·埃利斯特雷弗·A·K·沃塔姆
Owner GLAXO GROUP LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com